The effects of intraperitoneal calcitriol on calcium and parathyroid hormone

Delmez, James A.; Dougan, C. Sue; Gearing, Barbara K.; Rothstein, Marcos; Windus, David W.; Rapp, Neville; Slatopolsky, Eduardo
March 1987
Kidney International;Mar1987, Vol. 31 Issue 3, p795
Academic Journal
Parathyroid suppression, by intraperitoneal calcitriol (1,25(OH)2D3) during peritoneal dialysis. The purpose of this study was to determine if parathyroid hormone (PTH) suppression could be achieved by increasing calcium mass transfer (Ca MT) with high dialysate Ca (4 mEq/liter) or via intraperitoneal (i.p.) 1,25(OH)2D3 in patients undergoing continuous ambulatory peritoneal dialysis. Eleven patients were dialyzed for two months with standard Ca dialysate (3.5 mEq/liter) followed by two months with 4.0 mEq/liter Ca, then by three months of i,p. 1,25(OH)2D3. During the latter period, patients were randomized to groups whose dialysate contained either 3.5 mEq/liter or 4.0 mEq/liter Ca. We found that 4.0 mEq/liter Ca dialysate more than doubled Ca MT (37 ± 17 mg/day to 84 ± 6 mg/day) leading to a modest fall (P < 0.05) in PTH levels (84 ± 5..5% of controls). Ionized calcium levels did not change. With i.p. 1,25(OH)2D3, however, ionized calcium rose significantly (P < 0.001) leading to a decline in PTH levels to 53.9 ± 7,9% of control values. Serum 1,25(OH)2D3 levels rose from undetectable to 47.7 ± 7.2 pg/dl (normal range 20 to 35). These studies indicate that increasing Ca MT using a 4.0 mEq/liter Ca dialysate leads to a small reduction in PTH concentrations. On the other hand, i.p. 1,25(OH)2D3 is well absorbed into the systemic circulation, raises ionized calcium levels, and leads to a marked suppression of PTH. Thus, i.p. 1,25(OH)2D3 may be a simple and effective means to suppress secondary hyperparathyroidism in patients undergoing CAPD.


Related Articles

  • Calcemic and phosphaturic response to parathyroid hormone in normal and chronically uremic dogs. Jacob, Allan I.; Gavellas, George; Canterbury, Janet; Bourgoigne, Jacques J. // Kidney International;Jul1982, Vol. 22 Issue 1, p21 

    It is well established that the calcemic response to parathyroid hormone (PTH) is blunted in chronic uremia and is corrected partially by 1,25(OH)2D treatment. Recent evidence suggests that PTH(1-34) and not PTH(1-84) may be the actual calcemic fragment. Equivalent doses of both peptides were...

  • Cinacalcet reduced serum calcium in hemodialysis patients with hyperparathyroidism.  // Endocrine Today;9/10/2008, Vol. 6 Issue 16, p22 

    The article discusses findings of a study conducted by researchers from the Hospital Universitario Reina Sofia in Cordoba, Spain, which examined the effect of cinacalcet on the parathyroid hormone-calcium curve in nine long-term hemodialysis patients with secondary hyperparathyroidism. It has...

  • Parathyroid hormone response to hypocalcemia in hemodialysis patients with osteomalacia. Andress, Dennis; Felsenfeld, Arnold J.; Voigts, Anne; Llach, Francisco // Kidney International;Sep1983, Vol. 24 Issue 3, p364 

    The parathyroid hormone response to hypocalcemia was investigated in hemodialysis patients with osteomalacia and compared to those with osteitis fibrosa. Hypocalcemia was induced during hemodialysis by employing a dialysate devoid of calcium. Patients with osteomalacia had a blunted maximum...

  • The calcemic response to PTH in the rat: Effect of elevated PTH levels and uremia. Bover, Jordi; Jara, Aquiles; Pedro Trinidad; Rodriguez, Mariano; Martin-Malo, Alejandro; Felsenfeld, Arnold J. // Kidney International;Aug1994, Vol. 46 Issue 2, p310 

    Secondary hyperparathyroidism (2° HPT) is a consistent funding in renal failure. A decreased calcemic response (CR) to parathyroid hormone (PTH) contributes to the development of 2° HPT. Since parathyroidectomy (PTX) corrects the decreased CR to PTH in azotemic animals, down-regulation of...

  • Calcimimetics, parathyroid hormone, and vascular calcification in chronic kidney disease. Coen, Giorgio // Kidney International;Nov2008, Vol. 74 Issue 10, p1229 

    Vascular calcification (VC) occurs frequently in chronic kidney disease, contributing to cardiovascular mortality. Numerous risk factors have been identified, including renal osteodystrophy and bone turnover, with low turnover as a main determinant. Other reports support high turnover as a...

  • Contrasting mammalian PTH promoters: identification of transcription factors controlling PTH gene expression. Koszewski, N. J.; Alimov, A. P.; Langub, M. C.; Park-Sarge, O.-K.; Malluche, H. H. // Clinical Nephrology;2005, Vol. 63 Issue 2, p158 

    Parathyroid hormone (PTH) is a key component in the maintenance of calcium and phosphate homeostasis. The steady-state expression of the PTH gene can be modeled as a balance between transcriptional activators and repressors. During renal failure, the gradual loss of kidney function is of ten...

  • Ratio of parathyroid hormone to 1 ,25-dihydroxycholecalciferol in early renal failure. Lucas, Philip A.; Brown, Richard C.; Woodhead, J. Stuart; Coles, Gerald A. // Kidney International Supplement;Dec1983, Issue 16, pS171 

    The article reports on the results of a study of ratio of parathyroid hormone to 1,25-dihydroxycholecalciferol in chronic renal failure (CRF). A description of the experimental setup and measurement methods is given. The article explains why the precise degree of renal impairment at which...

  • Skeletal resistance to the calcemic action of parathyroid hormone in uremia: Role of 1,25(OH)2D3. Massry, Shaul G.; Stein, Robert; Garty, Jacob; Arieff, Allen I.; Coburn, Jack W.; Norman, Anthony W.; Friedler, Robert M. // Kidney International;Jun1976, Vol. 9 Issue 6, p467 

    Studies were carried out to investigate the role of 1,25 dihydroxy vitamin D [1,25(OH)2D3] in the skeletal resistance to the calcemic action of parathyroid hormone. The change in serum calcium after the intravenous infusion of 2 U of parathyroid extract (PTE)/kg body wt/hr for eight hours was...

  • The interaction of parathyroid hormone and aluminum in renal osteodystrophy. Slatopolsky, Eduardo // Kidney International;Mar1987, Vol. 31 Issue 3, p842 

    Studies the interaction of parathyroid hormone and aluminum in renal osteodystrophy. Presentation of a case which illustrates one of the major complications of chronic hemodialysis; Pathologic manifestations of renal osteodystrophy; Emphasis on the importance of controlling phosphorus in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics